{
    "id": 3208,
    "fullName": "DDR2 L239R",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "DDR2 L239R lies within the extracellular domain of the Ddr2 protein (UniProt.org). L239R results in transforming activity in cell culture (PMID: 22328973), and therefore, is predicted to result in a gain of Ddr2 protein function.",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4921,
        "geneSymbol": "DDR2",
        "terms": [
            "DDR2",
            "MIG20a",
            "NTRKR3",
            "TKT",
            "TYRO10",
            "WRCN"
        ]
    },
    "variant": "L239R",
    "createDate": "02/18/2015",
    "updateDate": "06/07/2019",
    "referenceTranscriptCoordinates": {
        "id": 147404,
        "transcript": "NM_001014796",
        "gDna": "chr1:g.162759840T>G",
        "cDna": "c.716T>G",
        "protein": "p.L239R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5095,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of lung squamous cell cancer cells harboring DDR2 L239R in culture (PMID: 22328973).",
            "molecularProfile": {
                "id": 3031,
                "profileName": "DDR2 L239R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5125,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 L239R in culture, with increased potency over either agent alone (PMID: 22328973).",
            "molecularProfile": {
                "id": 3031,
                "profileName": "DDR2 L239R"
            },
            "therapy": {
                "id": 3756,
                "therapyName": "Nilotinib + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5097,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 L239R in culture (PMID: 22328973).",
            "molecularProfile": {
                "id": 3031,
                "profileName": "DDR2 L239R"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1803,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited proliferation of lung squamous cell carcinoma cells harboring a DDR2 L239R mutation in culture (PMID: 22328973).",
            "molecularProfile": {
                "id": 3031,
                "profileName": "DDR2 L239R"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5104,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 L239R in culture (PMID: 22328973).",
            "molecularProfile": {
                "id": 3031,
                "profileName": "DDR2 L239R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5089,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of DDR2 T654M in lung squamous cell cancer cells harboring DDR2 L239R resulted in decreased sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973).",
            "molecularProfile": {
                "id": 20266,
                "profileName": "DDR2 L239R DDR2 T654M"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19078,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DDR2 T654I was identified as an acquired mutation in lung squamous cell carcinoma cells harboring DDR2 L239R that became resistant to Sprycel (dasatinib) in culture (PMID: 24296828).",
            "molecularProfile": {
                "id": 33919,
                "profileName": "DDR2 L239R DDR2 T654I"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 2149,
                    "pubMedId": 24296828,
                    "title": "Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24296828"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3031,
            "profileName": "DDR2 L239R",
            "profileTreatmentApproaches": [
                {
                    "id": 19638,
                    "name": "DDR2 inhibitor",
                    "profileName": "DDR2 L239R"
                }
            ]
        },
        {
            "id": 20266,
            "profileName": "DDR2 L239R DDR2 T654M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33919,
            "profileName": "DDR2 L239R DDR2 T654I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 147400,
            "transcript": "XM_006711344",
            "gDna": "chr1:g.162759840T>G",
            "cDna": "c.716T>G",
            "protein": "p.L239R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 147401,
            "transcript": "XM_011509586",
            "gDna": "chr1:g.162759840T>G",
            "cDna": "c.716T>G",
            "protein": "p.L239R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 147402,
            "transcript": "XM_011509587",
            "gDna": "chr1:g.162759840T>G",
            "cDna": "c.716T>G",
            "protein": "p.L239R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 147403,
            "transcript": "XM_011509588",
            "gDna": "chr1:g.162759840T>G",
            "cDna": "c.716T>G",
            "protein": "p.L239R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 147404,
            "transcript": "NM_001014796",
            "gDna": "chr1:g.162759840T>G",
            "cDna": "c.716T>G",
            "protein": "p.L239R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 147405,
            "transcript": "NM_006182",
            "gDna": "chr1:g.162759840T>G",
            "cDna": "c.716T>G",
            "protein": "p.L239R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}